394 related articles for article (PubMed ID: 38268926)
1. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
Yin J; Gu T; Chaudhry N; Davidson NE; Huang Y
Front Immunol; 2023; 14():1325615. PubMed ID: 38268926
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
5. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
6. Triune Nanomodulator Enables Exhausted Cytotoxic T Lymphocyte Rejuvenation for Cancer Epigenetic Immunotherapy.
Li J; Zhao Q; Zhang N; Wu L; Wang Q; Li J; Pan Q; Pu Y; Luo K; Gu Z; He B
ACS Nano; 2024 May; 18(20):13226-13240. PubMed ID: 38712706
[TBL] [Abstract][Full Text] [Related]
7. A review of immune checkpoint blockade in breast cancer.
Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics Regulates Antitumor Immunity in Melanoma.
Chen Y; Yi X; Sun N; Guo W; Li C
Front Immunol; 2022; 13():868786. PubMed ID: 35693795
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
Zhou L; Yu CW
Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities.
Tien FM; Lu HH; Lin SY; Tsai HC
J Biomed Sci; 2023 Jan; 30(1):3. PubMed ID: 36627707
[TBL] [Abstract][Full Text] [Related]
12. Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer.
Luo H; Shan J; Zhang H; Song G; Li Q; Xu CX
Semin Cancer Biol; 2022 Nov; 86(Pt 3):960-970. PubMed ID: 35189321
[TBL] [Abstract][Full Text] [Related]
13. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers.
Lee DY; Salahuddin T; Iqbal J
Curr Oncol; 2023 Feb; 30(2):2127-2143. PubMed ID: 36826125
[TBL] [Abstract][Full Text] [Related]
14. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
15. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Tao S; Liang S; Zeng T; Yin D
Front Immunol; 2022; 13():1043667. PubMed ID: 36685594
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
18. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
Liu M; Zhou J; Chen Z; Cheng AS
J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment.
Vitiello GAF; Ferreira WAS; Cordeiro de Lima VC; Medina TDS
Front Immunol; 2021; 12():782852. PubMed ID: 34925363
[TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]